![Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria | SpringerLink Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40273-020-00929-z/MediaObjects/40273_2020_929_Fig1_HTML.png)
Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria | SpringerLink
![AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says | Fierce Pharma AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1627065958/Astrazeneca%20.jpg/Astrazeneca%20.jpg?VersionId=0SwzcAMXxVbrlhBQSgVZfGPGnvYHeDyb)
AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says | Fierce Pharma
![Soliris Shown to Ease Symptoms of aHUS Flare in Man, 20: Report | Researchers Say Soliris Should Be Available Despite High Cost | AHUS News Soliris Shown to Ease Symptoms of aHUS Flare in Man, 20: Report | Researchers Say Soliris Should Be Available Despite High Cost | AHUS News](https://ahusnews.com/wp-content/uploads/2021/11/IV-1.png)
Soliris Shown to Ease Symptoms of aHUS Flare in Man, 20: Report | Researchers Say Soliris Should Be Available Despite High Cost | AHUS News
Full article: A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome
![Clinical Utility and Potential Cost Savings of Pharmacologic Monitoring of Eculizumab for Complement-Mediated Thrombotic Microangiopathy - Mayo Clinic Proceedings: Innovations, Quality & Outcomes Clinical Utility and Potential Cost Savings of Pharmacologic Monitoring of Eculizumab for Complement-Mediated Thrombotic Microangiopathy - Mayo Clinic Proceedings: Innovations, Quality & Outcomes](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/243068f4-3d4b-4480-9979-2e32890e1dd6/gr1.jpg)